Patients with T2D often undergo more frequent clinical monitoring and earlier initiation of therapies with established cardiorenal benefits, such as SGLT2-i and GLP1-RA, which may mitigate the excess risk traditionally associated with diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.